The Union Ministry of AYUSH announced that AYUSH 64 could help meaningfully treat “asymptomatic, mild and moderate COVID-19 infections as an adjunct to standard care” and the AYUSH ministry has launched a nationwide campaign to distribute AYUSH 64 and a phytotherapeutic liquid called ‘Kabasura Kudineer’.
About the AYUSH 64
- AYUSH-64 is an Ayurvedic formulation which was developed by the Central Council for Research in Ayurvedic Sciences (CCRAS), the apex body for research in Ayurveda under the Ministry of Ayush, for management of Malaria
- Council of Scientific and Industrial Research (CSIR) and other research organizations and medical colleges across the country collaborated with CCRAS to conduct the trials.
- AYUSH-64, a drug developed for curing malaria in 1980.
- The trials showed AYUSH 64 has notable antiviral, immune-modulator and antipyretic properties.
- It is found to be useful in the treatment of asymptomatic, mild and moderate COVID-19 infection.
- Consequently, the drug is now repurposed for COVID-19.
Standard care
- It is technically called as ‘standard of care’.
- According to the US National Cancer Institute, it is the treatment that experts agree is appropriate, accepted, and widely used.”
|
About the Kabasura Kudineer
- Kabasura Kudineer is a traditional formulation used by Siddha practitioners for effectively managing common respiratory health.
- This is a combination of 15 herbs.
- This herbal formulation helps in relieving symptoms associated with respiratory health.
- It is considered as the best immunity booster
- Its anti-bacterial effect helps to combat cold & cough.
- Kabasura Kudineer is included in Guidelines for Siddha Practitioners for Covid 19 issued by the ministry of Ayush.
